JP5214312B2 - 固形製剤およびその製造方法 - Google Patents
固形製剤およびその製造方法 Download PDFInfo
- Publication number
- JP5214312B2 JP5214312B2 JP2008106895A JP2008106895A JP5214312B2 JP 5214312 B2 JP5214312 B2 JP 5214312B2 JP 2008106895 A JP2008106895 A JP 2008106895A JP 2008106895 A JP2008106895 A JP 2008106895A JP 5214312 B2 JP5214312 B2 JP 5214312B2
- Authority
- JP
- Japan
- Prior art keywords
- coating layer
- biocompatible
- active ingredient
- nanoparticles
- inner core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007787 solid Substances 0.000 title claims description 90
- 238000002360 preparation method Methods 0.000 title claims description 46
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 239000002105 nanoparticle Substances 0.000 claims description 165
- 239000004480 active ingredient Substances 0.000 claims description 134
- 239000011247 coating layer Substances 0.000 claims description 130
- 229920000642 polymer Polymers 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 29
- 239000011343 solid material Substances 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 239000011248 coating agent Substances 0.000 claims description 27
- 229920000249 biocompatible polymer Polymers 0.000 claims description 24
- 238000000748 compression moulding Methods 0.000 claims description 16
- 229920001577 copolymer Polymers 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 15
- 239000004310 lactic acid Substances 0.000 claims description 15
- 235000014655 lactic acid Nutrition 0.000 claims description 15
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 14
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 14
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 9
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 230000000536 complexating effect Effects 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 5
- 239000004626 polylactic acid Substances 0.000 claims description 5
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000005591 trimellitate group Chemical group 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000011162 core material Substances 0.000 description 76
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 51
- 239000002904 solvent Substances 0.000 description 36
- 210000000936 intestine Anatomy 0.000 description 33
- 239000003814 drug Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 29
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 28
- 239000007853 buffer solution Substances 0.000 description 28
- 239000011246 composite particle Substances 0.000 description 23
- 210000002784 stomach Anatomy 0.000 description 21
- 239000012085 test solution Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 239000012530 fluid Substances 0.000 description 15
- 238000002156 mixing Methods 0.000 description 15
- 238000010828 elution Methods 0.000 description 14
- 229960005489 paracetamol Drugs 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000004570 mortar (masonry) Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 238000007440 spherical crystallization Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 230000006355 external stress Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 238000011197 physicochemical method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000011370 conductive nanoparticle Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124633 peptidic drug Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
[PLGAナノ粒子の調製]
PLGA(PLGA7520、乳酸/グリコール酸=75/25、分子量20000、和光純薬工業製)100mgをアセトン2mLとエタノール1mLの混合液に溶解し、PLGA溶液を得た。一方、ポリビニルアルコール(PVA403、クラレ製)1mgを精製水50mgに溶解し、貧溶媒(外水相)とした。この外水相に、400rpmの攪拌下、PLGA溶液を滴下し(4mL/min)、PLGAナノ粒子(生体適合性ナノ粒子)の懸濁液を得た。
PLGAナノ粒子粉末を精製水に懸濁して得られた懸濁液と、メタクリル酸コポリマーLの懸濁液(オイドラギットL30D55、デグサ製)とを、PLGAナノ粒子とメタクリル酸コポリマーLの重量比が1:3となるよう混合した後、上記同様に凍結乾燥し、PLGAナノ粒子とメタクリル酸コポリマーLとの複合化粒子を得た。
得られた複合化粒子50mgを、直径8mmの上杵、下杵及び臼を装着された油圧プレス式打錠機(ES−10TP、エイシン製)により、圧縮圧100kNで打錠し、参考例1のサンプルを得た。
[複合化粒子の圧縮成形]
参考例1と同様に調製したPLGAナノ粒子粉末を、メタクリル酸コポリマーLの粉末(オイドラギットL100−55、デグサ製)と重量比が1:3となるよう乳鉢で物理混合し、得られた混合粉末50mgを打錠し、参考例2のサンプルを得た。
0.2mol/Lリン酸二水素カリウム試液と0.2mol/L水酸化ナトリウム試液をpH計測器でpHを測定しながら交互に混ぜ、約pH7.4の緩衝液(pH7.4緩衝液)を調製した。
試験管にpH7.4緩衝液を10mL入れ、参考例1及び参考例2のサンプルを投入し、試験液を37℃に保ちながら水平に振とうした。投入から1.5時間、3時間、6時間経過後に試験液を1mL採取し、各採取後、試験管内へpH7.4緩衝液を1mL加えた。
[内核用顆粒の製造]
モデル薬物としてアセトアミノフェンを用いた。まず、ヒドロキシプロピルセルロース(HPC)70gを精製水1000gに溶解し、7%HPC溶液を調整した。次に、転動流動層造粒乾燥・コーティング装置(マルチプレックス、パウレック製)に乳糖400gとアセトアミノフェン47gを入れ、7%HPC溶液を用いて流動層造粒法により造粒した。そして、この造粒品392gに対しアエロジル2gとステアリン酸マグネシウム2gを混合して内核用顆粒とした。
上記内核用顆粒と、参考例1で得られた複合化粒子とを用い、表3に示す処方で有核錠を製造した。卓上型単発式打錠機(MINIPRESS MII、RIVA製)を用い、まず、直径6mmの臼及び杵を装着し、かかる臼内に内核用顆粒を入れ、15kNでアセトアミノフェン層(内核錠、内核固形物)を製造した。次に、複合化粒子の一部を上記直径8mmの臼に入れて15kNで押し固め、その中心部にアセトアミノフェン層を置き、さらに周囲と上面に残りの複合化粒子を充填してアセトアミノフェン層の周囲を覆い、打錠した。こうして、被覆層中に複合化粒子を配合した表3に示す実施例1〜実施例5の有核錠(固形製剤)を製造した。
[有核錠の製造]
一方、実施例1〜実施例5で製造した内核用顆粒を用い、表3に示す処方で、被覆層としてメタクリル酸コポリマーL粉末(オイドラギットL100−55、デグサ製)のみを用い、実施例1〜実施例5と同様にして、内核固形物をメタクリル酸コポリマーL粉末により被覆し、比較例の有核錠を製造した。
塩化ナトリウム2gに塩酸70mL及び精製水を加えて溶解し、1000mLとすることにより、pH約1.2の緩衝液(pH1.2緩衝液)を得た。
0.2mol/Lリン酸二水素カリウム試液250mLに0.2mol/L水酸化ナトリウム試液118mL及び水を加えて1000mLとし、pH約6.8の緩衝液(pH6.8緩衝液)を得た。
pH1.2緩衝液及びpH6.8緩衝液を試験液とし、実施例1〜実施例5の錠剤を用いて溶出試験を行い、被覆層の厚みと活性成分の溶出挙動との関係について調べた(n=3)。まずpH1.2緩衝液40mLに実施例1〜実施例5の錠剤を投入し、上記参考例と同様に37℃に保ちながら水平に振とうし、10分、20分、30分、45分、1時間、1.5時間、2時間経過後に試験液1mLを採取した。
[有核錠の製造]
参考例1と同様に調製したPLGAナノ粒子の懸濁液とメタクリル酸コポリマーLの懸濁液との混合液に、表4の処方に示すようにデキストラン(分子量10200)を添加して溶解し、参考例1と同様に凍結乾燥を行い、複合化粒子を得た。かかる複合化粒子と実施例1〜実施例5で製造した内核用顆粒とを用い、表4に示す処方で、実施例1〜実施例5と同様にして有核錠を調製した。なお、実施例6〜実施例8では被覆層に対してデキストランを20重量%配合し、実施例9、実施例10では30重量%配合した。
上記pH1.2緩衝液及びpH6.8緩衝液を試験液とし、実施例6〜実施例10の錠剤を用いて溶出試験を行い、水溶性物質の被覆層への配合量と活性成分の溶出挙動との関係について調べた(n=3)。まず、実施例6〜実施例10の錠剤をpH1.2緩衝液に投入し、10分、20分、30分、45分、1時間、1.5時間、2時間経過後に試験液1mLを採取した。
Claims (10)
- 活性成分を含む内核固形物を、生体適合性ナノ粒子と、該生体適合性ナノ粒子と複合化された腸溶性高分子と、を含む被覆層で被覆した固形製剤。
- 前記生体適合性ナノ粒子を形成する生体適合性高分子が、ポリ乳酸、ポリグリコール酸、乳酸・グリコール酸共重合体、若しくは乳酸・アスパラギン酸共重合体のいずれか1種あるいは2種以上であることを特徴とする請求項1に記載の固形製剤。
- 前記腸溶性高分子が、ヒドロキシプロピルメチルセルロースフタレート、ヒドロキシプロピルメチルセルロースアセテートサクシネート、カルボキシメチルエチルセルロース、セルロースアセテートフタレート、セルロースアセテートトリメリテート、メタクリル酸コポリマー、ポリビニルアセテートフタレートのいずれか1種あるいは2種以上であることを特徴とする請求項1または2に記載の固形製剤。
- 前記生体適合性ナノ粒子にも活性成分が封入されていることを特徴とする請求項1〜3のいずれかに記載の固形製剤。
- 前記内核固形物にも生体適合性ナノ粒子を含み、該生体適合性ナノ粒子には前記内核固形物に含まれる活性成分の少なくとも一部が封入されていることを特徴とする請求項1〜4のいずれかに記載の固形製剤。
- 前記内核固形物が錠剤または丸剤であることを特徴とする請求項1〜5のいずれかに記載の固形製剤。
- 前記被覆層が圧縮成形により形成されることを特徴とする請求項6に記載の固形製剤。
- 前記被覆層が水溶性物質を含むことを特徴とする請求項1〜7のいずれかに記載の固形製剤。
- 生体適合性高分子から生体適合性ナノ粒子を形成する第1工程と、
前記生体適合性ナノ粒子を腸溶性高分子と複合化する第2工程と、
活性成分を含む内核固形物を、前記生体適合性ナノ粒子と、該生体適合性ナノ粒子と複合化された腸溶性高分子と、を含む被覆層で被覆する第3工程と、
を含む固形製剤の製造方法。 - 前記第3工程が、圧縮成形により前記内核固形物を前記被覆層で被覆することを特徴とする請求項9に記載の固形製剤の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008106895A JP5214312B2 (ja) | 2008-04-16 | 2008-04-16 | 固形製剤およびその製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008106895A JP5214312B2 (ja) | 2008-04-16 | 2008-04-16 | 固形製剤およびその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009256239A JP2009256239A (ja) | 2009-11-05 |
JP5214312B2 true JP5214312B2 (ja) | 2013-06-19 |
Family
ID=41384145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008106895A Active JP5214312B2 (ja) | 2008-04-16 | 2008-04-16 | 固形製剤およびその製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5214312B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132096B1 (en) * | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
AU2015341070B2 (en) * | 2014-10-28 | 2019-11-21 | Merck Patent Gmbh | Preparation of nanoparticles-releasing enteric microparticles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
JP2006206449A (ja) * | 2005-01-25 | 2006-08-10 | Pharma Polytech:Kk | コーティング用粉末、その製造方法及び該コーティング用粉末含有製剤 |
JP4878463B2 (ja) * | 2005-09-13 | 2012-02-15 | ホソカワミクロン株式会社 | ペプチドホルモン封入ナノ粒子を含む医薬製剤及びその製造方法 |
-
2008
- 2008-04-16 JP JP2008106895A patent/JP5214312B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009256239A (ja) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7144585B1 (en) | Cilostazol preparation | |
US8709996B2 (en) | Pharmaceutical treatment process using chitosan or derivative thereof | |
JP4077803B2 (ja) | 多孔質アパタイト粒状物を用いる安定で、味覚をマスクした製薬剤形 | |
US9125803B2 (en) | Gastric release pulse system for drug delivery | |
JP4748839B2 (ja) | シロスタゾール製剤 | |
US9839617B2 (en) | Nanoencapsulation of hydrophilic active compounds | |
US7138143B1 (en) | Coated preparation soluble in the lower digestive tract | |
JPH09511767A (ja) | 新規な経口用の医薬使用形態 | |
JP2004505918A5 (ja) | ||
WO1999016448A1 (fr) | Comprime de theophylline a liberation prolongee | |
WO2006080481A1 (ja) | マルチプルユニット型経口徐放性製剤及びその製造方法 | |
KR20180062063A (ko) | 서방형 항암용 약학 조성물 | |
JP2000510488A (ja) | 改良投薬ユニット | |
WO2003053420A1 (en) | Multiple-pulse extended release formulations of clindamycin | |
Rafiee et al. | An overview of microparticulate drug delivery system and its extensive therapeutic applications in diabetes | |
EA009695B1 (ru) | Гранулы, содержащие гидрохлорид венлафаксина | |
JP5214312B2 (ja) | 固形製剤およびその製造方法 | |
Mehta et al. | Solvent evaporation technique: An innovative approach to increase gastric retention | |
CN101810586B (zh) | 左旋多巴甲酯缓释微球组合物及其制备方法 | |
JP3929522B2 (ja) | 難水溶性薬物の徐放性製剤 | |
CN114681406A (zh) | 一种卡利拉嗪长效缓释微球及其制备方法 | |
JP3592723B2 (ja) | 非崩壊・持続性カプセル製剤 | |
JP2638604B2 (ja) | 徐放性製剤 | |
JPH0130A (ja) | 徐放性製剤 | |
Sharma et al. | Microparticle Drug Delivery: A Review of The System and Its Wide Range of Therapeutic Applications in Diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090722 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110316 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5214312 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160308 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |